⬥ Ardy Arianpour ⬥’s Post

𝗔 𝗕𝗲𝗮𝗰𝗼𝗻 𝗼𝗳 𝗛𝗼𝗽𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗙𝗶𝗴𝗵𝘁 𝗔𝗴𝗮𝗶𝗻𝘀𝘁 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀: 𝗙𝗗𝗔 𝗔𝗽𝗽𝗿𝗼𝘃𝗲𝘀 𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆'𝘀 𝗡𝗲𝘄 𝗗𝗿𝘂𝗴❗ This week brought a wave of relief and excitement for the millions of families battling Alzheimer's disease. The FDA finally approved Eli Lilly's 𝗱𝗼𝗻𝗮𝗻𝗲𝗺𝗮𝗯 (𝙗𝙧𝙖𝙣𝙙 𝙣𝙖𝙢𝙚 𝙆𝙞𝙨𝙪𝙣𝙡𝙖), expanding the limited treatment options for this debilitating condition. 💊 For years, we've witnessed the heartbreak of this disease with few effective treatments available. Kisunla's approval marks a significant breakthrough, offering a chance to slow the progression and potentially improve the quality of life for patients. 🧴 This new drug joins a similar one from Biogen, giving patients more choices and hope for the future. While there's still a long way to go in finding a cure, this is a monumental step forward. Let's celebrate this scientific advancement and keep pushing for even better outcomes! 👨⚕️ Here's to the researchers, scientists, and advocates who haven't given up on finding a cure! This is a testament to their unwavering dedication. 𝗣.𝗦 Share this post if you know someone who has been impacted by Alzheimer's. Together, we can raise awareness and support the fight for a cure. #AlzheimersAwareness #FDAApproval #NewTreatmentOption #HopeForAlzheimers #CureAlzheimers #ThankYouResearchers #WeCanDoThisTogether

Start matching your medications to your DNA!

How can #biopharma companies tell their story to achieve #earnedmedia success? Look no further than this story on Eli Lilly’s Alzheimer’s drug donanemab. - They provided access to the scientists to discuss the long journey with many challenges and successes of researching the disease and taking the drug through clinical trials. - They provided anecdotes dating back three decades that demonstrated their long-term commitment to treating Alzheimer’s even when there were doubts they would succeed. - They shared forward-looking messaging that conveys understanding that there is much more work to do and that they are positioned to continue to lead in this area. #Mediarelations #HealthCommunications

Join us on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

🚀 Thrilling News in Alzheimer's Research! 🚀 I'm excited to share two significant updates in the fight against Alzheimer's disease: FDA Advisors Recommend Donanemab. This recommendation is a major milestone, a promising new treatment for Alzheimer's. This progress brings hope to millions affected by this challenging disease and underscores the importance of ongoing clinical research. https://lnkd.in/gBwkBbiS The European Medicines Agency (EMA) hosted a critical workshop focused on the clinical investigation of medicines for the treatment of Alzheimer's disease. This workshop aimed to improve the design and execution of clinical trials, fostering innovation and accelerating the development of effective therapies. Everyone who researches this disease can take an incredible opportunity for professionals in the clinical trial field to gain valuable insights and contribute to the advancement of treatments for this challenging disease. This workshop and relevant valuable documents were critical topics and fostered discussions that aimed to improve the design and execution of clinical trials, ultimately accelerating the development of effective therapies for Alzheimer's disease. Let's continue to support and participate in these groundbreaking efforts to improve the lives of those affected by Alzheimer's. 🌍🧠💊 #ClinicalTrials #AlzheimersDisease #HealthcareInnovation #EMA #MedicalResearch #ClinicalInvestigation #AlzheimersTreatment #Healthcare #GlobalCRO #CNRResearch #FDA #씨엔알리서치 #글로벌CRO #글로벌임상시험 #다국가임상시험 #알츠하이머 #MFDS #한국임상시험 #유럽임상시험

[LOG IN NOW] Agitation associated with dementia due to Alzheimer's disease: An expert discusses management considerations and current guidelines is about to begin! Gain insights into managing agitation in Alzheimer's patients from experts in the field. See you there soon! https://brnw.ch/21wK26M Otsuka Pharmaceutical Companies (U.S.) #LTC #AgitationinAlzheimers #Dementia #GuidanceofPatients

This week, Eli Lilly and Company’s donanemab received unanimous support from an FDA advisory committee in favor of its efficacy and positive benefit-risk profile for patients with mild cognitive impairment and mild dementia. The committee praised donanemab as an innovative therapy and as industry stakeholders, we applaud this development, signifying a positive step towards an effective treatment for Alzheimer’s. We remain committed to collaborating with industry leaders to achieve a common goal - to change the lives of millions suffering from Alzheimer's by striving to deliver early diagnoses to access effective treatments. To learn about donanemab's FDA approval, read more here: https://lnkd.in/gnVypxSb #Alzheimers #DigitalBiomarkers #Altoida #DigitalHealth #MedTech #DigitalHealth #HealthTech #HealthcareInnovation